New Delhi, Aug 24 (PTI) India''s first mRNA-based COVID-19 vaccine candidate HGCO19 by Gennova Biopharmaceuticals Ltd has been granted approval for Phase 2/3 clinical trails, the Department of Biotechnology (DBT) said on Tuesday.
The Pune-based biotechnology company had submitted the interim clinical data of the vaccine''s Phase 1 study to the Central Drugs Standard Control Organisation (CDSCO), it said.https://www.outlookindia.com/newsscroll/gennovas-mrnabased-covid19-...